IRIS
SAVARINO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 40.317
Totale 40.317
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 40.317
Totale 40.317
Salva come PNG Salva come JPEG
Città #
Genova 33.728
Rapallo 4.096
Genoa 2.431
Bordighera 62
Totale 40.317
Salva come PNG Salva come JPEG
Nome #
Hepatobiliary and Pancreatic: A rare cause of portal hypertension. 168
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 156
Time pattern of gastric acidity in Barrett's esophagus 149
Vigor of peristalsis during multiple rapid swallows is inversely correlated with acid exposure time in patients with NERD 146
5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for “best evidence”? 145
Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD) 143
Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis 142
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. 142
13C-mixed triglyceride (13C-MTG) breath-test (BT) in Cystic Fibrosis (CF). 139
Alginate controls heartburn in patients with erosive and nonerosive reflux disease. 138
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 137
A pharmacodynamic study of two omeprazole regimens suitable for long-term treatment of duodenal ulcer. 136
Positive PET in a patient with esophageal leiomyoma. 136
Burden of illness in Italian patients with gastro-oesophageal reflux disease. 135
Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure. 134
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 134
Circadian monitoring of gastric juice mutagenicity. 134
Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. 133
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 133
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 132
Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. 132
Barrett's esophagus in 2016: From pathophysiology to treatment 130
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure 129
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 129
Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn 128
Ilaprazole for the treatment of gastro-esophageal reflux 128
Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. 127
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. 125
NERD: an umbrella term including heterogeneous subpopulations. 125
Measurement of oro-caecal transit time by magnetic resonance imaging. 125
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 125
CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. 125
OAM for cure of Helicobacter pylori infection. 124
Can artificial neural networks be beneficial in diagnosing gastro-oesophageal reflux disease? 124
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 123
New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. 123
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. 122
Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group 122
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 122
Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. 122
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study 122
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs pantoprazole. 121
Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. 121
Blessed are those who have not seen and yet have believed 121
24-hour study of intragastric acidity in duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry. 121
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 121
A comparison of the effects on intragastric acidity of bedtime or dinnertime administration of a once daily dose of famotidine. 120
Antimony and glass pH electrodes can be used interchangeably in 24-hour studies of gastric acidity. 120
Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. 120
Breath tests to assess alcoholic liver disease. 120
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. 119
External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis 119
Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole. 119
Circadian reduction of chromium in the gastric environment. 119
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 119
Esophageal acid exposure still plays a major role in patients with NERD. 119
Nevoid Basal Cell Carcinoma Syndrome in infants: improving diagnosis. 118
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 118
Once and twice daily doses of H2 antagonists revisited, using continuous intragastric pH monitoring. 118
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 118
A study of 4-and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication 118
Are duodenal ulcer seasonal fluctuations paralleled by seasonal changes in 24-hour gastric acidity and Helicobacter pylori infection? 117
A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. 117
An independent validation of the mortality score for the short-term prognostic prediction in patients with chronic hepatitis C virus infection and advanced liver disease 116
An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. 116
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 116
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 116
Acid and gastric metaplasia in the duodenum 115
Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori 115
Influence of time of dinner on nocturnal gastric pH. 115
The relevance of weakly acidic reflux in patients with Barrett's esophagus. 115
24-H comparison between pH values of continuous intraluminal recording and simultaneous gastric aspiration. 115
Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. 114
Lansoprazole vs omeprazole for gastro.oesophageal reflux disease: a pH-metric comparison. 114
Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up 114
Processing gastric pH measurements. 114
Discriminant value of dyspepsia subgroups. 114
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 114
Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer. 114
Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. 114
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 114
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. 114
Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors 113
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 113
Helicobacter pylori and acid secretion. 113
Feasibility of the cut-and-push method for removing large caliber, soft, percutaneous endoscopic gastrostomy devices. 113
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 113
A safety review of proton pump inhibitors to treat acid-related digestive diseases 113
Nocturnal acid breakthrough in subjects taking PPI b.i.d. 113
H2 antagonist non-responders. 112
The pathophysiologic role of nocturnal acid secretion in gastric ulcers. 112
Technical performance of colonoscopy: the key role of sedation/analgesia and other quality indicators. 112
Hepatocellular carcinoma in patients without cirrhosis in Italy. 112
Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. 112
Helicobacter pylori infection is not involved in the pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. 112
Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. 112
Are proton pump inhibitors really so dangerous? 112
Proton pump inhibitor failure: why does it occur and how can it be managed ? 111
A comparison of five maintenance therapies for reflux esophagitis 111
Absence of tolerance in duodenal ulcer patients treated for 28 days with a bedtime dose of roxatidine or ranitidine. 111
Totale 12.266
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.206
article - articoli 93.290
book - libri 322
conference - conferenze 1.335
curatela - curatele 0
other - altro 5.113
patent - brevetti 0
selected - selezionate 0
volume - volumi 146
Totale 200.412
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.201 0 0 0 0 0 0 0 0 0 0 1.224 977
2019/202012.164 520 304 577 815 1.113 1.260 1.858 845 1.089 2.088 1.197 498
2020/20213.251 186 362 295 333 174 294 123 332 317 354 224 257
2021/20225.241 161 297 378 744 235 408 388 1.125 212 497 177 619
2022/20234.913 530 265 60 424 947 890 6 379 886 32 437 57
2023/20241.689 117 313 51 223 183 396 128 99 138 39 2 0
Totale 40.857